Watch below our interview with Dr. Sharlene Dong from UT Southwestern Medical Center, who shared with us the results from her poster presentation at EHA 2024: 'Real-World Carfilzomib Prescribing Patterns And Outcomes For Patients With Relapsed Refractory Multiple Myeloma'.
This study aimed to understand the most common dosing schedules of carfilzomib (Kyprolis, Amgen) being administered in the US in both academic and community cancer centers, why they change from patient to patient, and determine the most effective one for patients with myeloma that has come back after treatment or stopped responding to treatment (relapsed/refractory).
The research also looked at what influences the decision about how often to give carfilzomib. These factors include:
Studies like Dr. Dong's are crucial because they look at how treatments really work in the lives of patients. This helps doctors understand which treatments are not only effective but also fit best with patients' daily routines and preferences. If you have questions about carfilzomib or your treatment plan, talk to your doctor. They can help you understand your options and make the best choices for your individual needs.
At HealthTree, we believe patients are essential research partners. Sharing your experiences through HealthTree Cure Hub can help advance our understanding of multiple myeloma and improve care for everyone affected by this disease.
Learn more about our research and how you can get involved:
HealthTree Active Research Projects
Sources:
Watch below our interview with Dr. Sharlene Dong from UT Southwestern Medical Center, who shared with us the results from her poster presentation at EHA 2024: 'Real-World Carfilzomib Prescribing Patterns And Outcomes For Patients With Relapsed Refractory Multiple Myeloma'.
This study aimed to understand the most common dosing schedules of carfilzomib (Kyprolis, Amgen) being administered in the US in both academic and community cancer centers, why they change from patient to patient, and determine the most effective one for patients with myeloma that has come back after treatment or stopped responding to treatment (relapsed/refractory).
The research also looked at what influences the decision about how often to give carfilzomib. These factors include:
Studies like Dr. Dong's are crucial because they look at how treatments really work in the lives of patients. This helps doctors understand which treatments are not only effective but also fit best with patients' daily routines and preferences. If you have questions about carfilzomib or your treatment plan, talk to your doctor. They can help you understand your options and make the best choices for your individual needs.
At HealthTree, we believe patients are essential research partners. Sharing your experiences through HealthTree Cure Hub can help advance our understanding of multiple myeloma and improve care for everyone affected by this disease.
Learn more about our research and how you can get involved:
HealthTree Active Research Projects
Sources:
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.